The research group led by Drs. Mitsuru Arase, Mari Murakami, and Prof. Kiyoshi Takeda (Graduate School of Medicine/ Immunology Frontier Research Center at The University of Osaka) revealed that transcription factors RUNX2 and BHLHE40 play crucial roles in inducing T cells involved in Crohn's disease.

A team of scientists at Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) has created a protein-based therapeutic tool  that could change the way we treat diseases caused by harmful or unnecessary cells. The new tool, published in Nature Biomedical Engineering, involves a synthetic protein called Crunch, short for Connector for Removal of Unwanted Cell Habitat. Crunch uses the body’s natural waste removal system to clear out specific target cells, offering hope for improved treatments for cancer, autoimmune diseases, and other diseases where harmful cells cause damage.

Pregnancy complications such as preeclampsia and preterm birth often arise during the late stage of pregnancy. However, researchers have primarily relied on placental cells from early pregnancy to study these conditions, which may not fully reflect the biology of late-stage complications. Now, a research team in Japan has successfully developed human placental stem cells from the smooth chorion (a part of the placenta) taken from full-term pregnancies. These new stem cells, called Ch-TS cells, share the same characteristics as placental stem cells from early pregnancy and can develop into the key cell types essential for proper placental function. This advancement allows scientists to study placental complications using cells from the actual time period when these complications occur, potentially leading to better understanding, earlier detection, and improved treatments for pregnancy-related conditions.